Key result
Cell, gene, and protein therapies show promise for cardiac repair in ischemic injury and heart failure.
In humans, the biological limitations to cardiac regenerative growth create both a clinical imperative--to offset cell death in acute ischemic injury and chronic heart failure--and a clinical opportunity; that is, for using cells, genes, and proteins to rescue cardiac muscle cell number or in other ways promote more efficacious cardiac repair. Recent experimental studies and early-phase clinical trials lend credence to the visionary goal of enhancing cardiac repair as an achievable therapeutic target.
No takes yet. Share an insight, caveat, or question.
Dimmeler et al. (2005) conducted a review in Acute ischemic injury and chronic heart failure. Cardiac regenerative therapies (cells, genes, and proteins) was evaluated. Recent studies suggest that enhancing cardiac repair using cells, genes, and proteins is an achievable therapeutic target for acute ischemic injury and chronic heart failure.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: